GlassScriptPhysician profile
Martin Camacho
NPI 1275613424
$1,432.54
in general payments reported to CMS, 2019-2025
18 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $587 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.55 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $526.52 | 2024-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $157.85 | 2024-2025 | Wainua, Farxiga |
| Abiomed | $119.18 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $100.38 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $86.82 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $84.31 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $70.43 | 2024 | Arcalyst |
| Lemaitre Vascular, INC. | $48.50 | 2025 | Artegraft Vascular Graft |
| Bayer Healthcare Pharmaceuticals INC. | $38.57 | 2025 | |
| Baylis Medical Technologies INC. | $29.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.18 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.45 | 2024 | Lifevest |
| Bolton Medical INC | $22.67 | 2024 | Treo Abdominal Stent-Graft System |
| Scpharmaceuticals INC. | $21.57 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.02 | 2024 | Amvuttra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $19.93 | 2024 | |
| Daiichi Sankyo INC. | $17.27 | 2024 | Injectafer |
| Novo Nordisk INC | $15.70 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.